| Title |
Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
|
|---|---|
| Published in |
BMC Cancer, July 2014
|
| DOI | 10.1186/1471-2407-14-550 |
| Pubmed ID | |
| Authors |
Yoshiya Horimoto, Atsushi Arakawa, Masahiko Tanabe, Hiroshi Sonoue, Fumie Igari, Koji Senuma, Emi Tokuda, Hideo Shimizu, Taijiro Kosaka, Mitsue Saito |
| Abstract |
Patients with luminal HER2-negative tumours have a favourable prognosis. However, there is a subpopulation in which poorer outcomes are obtained with endocrine therapy alone. This subpopulation is considered to benefit from chemotherapy. However, the significance of chemotherapy for those with luminal tumours has decreased due to recent changes in treatment strategies. Thus, it is often difficult to determine whether we should recommend chemotherapy to such patients in clinical practice. We investigated Ki67 expression, as a means of predicting the responses of luminal HER2-negative breast cancer patients to neo-adjuvant chemotherapy (NAC), in order to identify a subpopulation that would benefit from these treatments. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | 5% |
| Unknown | 20 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 4 | 19% |
| Student > Bachelor | 4 | 19% |
| Researcher | 4 | 19% |
| Other | 2 | 10% |
| Student > Doctoral Student | 1 | 5% |
| Other | 4 | 19% |
| Unknown | 2 | 10% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 48% |
| Agricultural and Biological Sciences | 3 | 14% |
| Nursing and Health Professions | 2 | 10% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Economics, Econometrics and Finance | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 3 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 August 2014.
All research outputs
#18,375,478
of 22,759,618 outputs
Outputs from BMC Cancer
#5,419
of 8,277 outputs
Outputs of similar age
#163,218
of 228,677 outputs
Outputs of similar age from BMC Cancer
#91
of 138 outputs
Altmetric has tracked 22,759,618 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,277 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,677 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 138 others from the same source and published within six weeks on either side of this one. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.